Detalhe da pesquisa
1.
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Int J Clin Oncol
; 27(1): 224-233, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599726
2.
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Eur J Haematol
; 105(3): 274-285, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32350909
3.
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Eur J Haematol
; 105(1): 35-46, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145111
4.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119237
5.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Blood
; 130(5): 597-605, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550039
6.
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Blood
; 130(24): 2610-2618, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054911
7.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943323
8.
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Br J Haematol
; 182(2): 231-244, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938772
9.
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Am J Hematol
; 2018 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29726031
10.
[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Rinsho Ketsueki
; 59(11): 2399-2407, 2018.
Artigo
em Japonês
| MEDLINE | ID: mdl-30531133
11.
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Br J Haematol
; 178(4): 571-582, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485007
12.
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.
Haematologica
; 102(10): 1767-1775, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751562
13.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood
; 124(7): 1047-55, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24904120
14.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Blood
; 124(7): 1038-46, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24920586
15.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Invest New Drugs
; 33(3): 652-63, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777468
16.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Lancet Oncol
; 15(13): 1503-1512, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456369
17.
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
Lupus Sci Med
; 11(1)2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38453421
18.
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Leukemia
; 36(1): 225-235, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34168284
19.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
J Clin Oncol
; 39(22): 2430-2442, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34111952
20.
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Clin Pharmacol Ther
; 105(2): 376-387, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29446068